Multiple pterygium syndromes (MPS) are a phenotypically and genetically heterogeneous group of rare Mendelian conditions characterized by multiple pterygia, scoliosis and congenital contractures of the limbs. MPS typically segregates as an autosomal recessive disorder but rare instances of autosomal dominant transmission have been reported. While several mutations causing recessive MPS have been identified, the genetic basis of dominant MPS remains unknown. We identified four families with dominantly transmitted MPS characterized by pterygia, camptodactyly of the hands, vertebral fusions, and scoliosis. Exome sequencing identified predicted protein-altering mutations in embryonic myosin heavy chain (MYH3) in three families. MYH3 mutations underlie distal arthrogryposis types 1, 2A and 2B, but all mutations reported to date occur in the head and neck domains. In contrast, two of the mutations found to cause MPS occurred in the tail domain. The phenotypic overlap among persons with MPS coupled with physical findings distinct from other conditions caused by mutations in MYH3, suggests that the developmental mechanism underlying MPS differs from other conditions and / or that certain functions of embryonic myosin may be perturbed by disruption of specific residues / domains. Moreover, the vertebral fusions in persons with MPS coupled with evidence of MYH3 expression in bone suggests that embryonic myosin plays a previously unknown role in skeletal development.
Multiple pterygium syndromes (MPS) are a phenotypically and genetically heterogeneous group of rare Mendelian conditions characterized by multiple pterygia, scoliosis and congenital contractures of the limbs. Most often, MPS occurs as a simplex case, and of reported multiplex families, the majority consist of multiple affected siblings born to unaffected parents, consistent with inheritance in an autosomal recessive pattern 1 . In very rare instances, MPS has been transmitted from an affected parent to an affected child, indicative of autosomal dominant transmission [2] [3] [4] [5] . In 1996, we revised the classification of distal arthrogryposis (DA) syndromes and categorized several additional conditions 6 Figure S1 ). To identify the gene(s) harboring mutations underlying DA8, we initially screened by Sanger sequencing the proband of each family for mutations in genes known to underlie lethal MPS (MIM 253290) and non-lethal Escobar-variant autosomal recessive MPS (MIM 265000) including CHRNG 7, 8 (MIM 100730), CHRND 9 (MIM 100720), CHRNA1 9 (MIM 100690) as well as IRF6 10 (MIM 607199), mutations in which cause popliteal pterygium syndrome (MIM 119500). No pathogenic mutations were found in any of these candidate genes. Next, we preformed exome sequencing on seven individuals in family A, three individuals in family B, and two affected individuals (III-5 and V-2) in family C ( Table 1 ; Figures 1 and 2; Figure S1 ). All studies were approved by the institutional review boards of the University of Washington and Seattle Children's Hospital; and informed consent was obtained from each participant.
In brief, one microgram of genomic DNA was subjected to a series of shotgun library construction steps, including fragmentation through acoustic sonication (Covaris), end-polishing (NEBNext End Repair Module), A-tailing (NEBNext dA-Tailing Module), and PCR amplification with ligation of 8 bp barcoded sequencing adaptors (Enzymatics Ultrapure T4 Ligase) for multiplexing. One microgram of barcoded shotgun library was hybridized to capture probes targeting ~36.5 Mb of coding exons (Roche Nimblegen SeqCap EZ Human Exome Library v2.0).
Library quality was determined by examining molecular weight distribution and sample concentration (Agilent Bioanalyzer). Pooled, barcoded libraries were sequenced via paired-end 50 bp reads with an 8 bp barcode read on Illumina HiSeq sequencers.
Demultiplexed BAM files were aligned to a human reference (hg19) using the Burrows-Wheeler Aligner (BWA) 0.6.2. Read data from a flow-cell lane were treated independently for alignment and QC purposes in instances where the merging of data from multiple lanes was required. All aligned read data were subjected to: (1) removal of duplicate reads (Picard MarkDuplicates v1.70) (2) indel realignment (GATK IndelRealigner v1.6-11-g3b2fab9); and (3) base quality recalibration (GATK TableRecalibration v1.6-11-g3b2fab9). Single nucleotide variant (SNV) detection and genotyping were performed using GATK UnifiedGenotyper (v1.6-11-g3b2fab9). SNV data for each sample were formatted (variant call format [VCF]) as "raw" calls that contained individual genotype data for one or multiple samples, and flagged using the filtration walker (GATK) to mark sites that were of lower quality and potential false positives (e.g. strand bias > -0.1, quality scores (Q50), allelic imbalance (ABHet≥0.75), long homopolymer runs (HRun>3), and/or low quality by depth (QD<5).
Because DA8 is extremely rare, with only four families reported to date 2-5 , we excluded SNVs with an alternative allele frequency >0.0001 in any population in the NHLBI Exome Sequencing Project Exome Variant Server (ESP6500/EVS), 1000 Genomes, or Exome Aggregation Consortium (ExAC v1.0) browser, or in an internal exome database of ~700 exomes. Additionally, SNVs that were flagged as low quality or potential false positives (quality score ≤ 30, long homopolymer run > 5, low quality by depth < 5, within a cluster of SNPs) were also excluded from analysis. Copy number variant (CNV) calls were generated from exome data with CoNIFER 11 . Variants were annotated with the SeattleSeq138 Annotation Server, and SNVs for which the only functional prediction label was intergenic, coding-synonymous, utr, near-gene, or intron were excluded. Individual genotypes with depth<6 or genotype quality<20 were treated as missing in the analysis.
To exclude known causes of multiple pterygium syndromes and well-known conditions that include pterygia, we first assessed the exome data for pathogenic variants in the genes previously screened by Sanger sequencing (IRF6, CHRNG, CHRNA1, and CHRND) as well as in RAPSN 9,12 (MIM 601592) and DOK7 13 (MIM 610285). No SNVs or CNVs in these genes segregated with DA8 in any of the three families tested. Next, we looked for novel and/or rare SNVs and CNVs in the same gene shared among affected probands. No genes with rare or novel variants were shared among all three families. Affected individuals in Families A and B were also screened for larger copy number variations (CNVs) by comparative genome-wide array genomic hybridization on the Illumina Infinium HumanCore-24 chip. No shared or overlapping CNVs were identified. Subsequently, we loosened our filtering criteria to include variants in genes that were shared by two out of three families and identified three candidate genes (SHPRH [MIM 608048], SLC5A9, MYH3) in families A and B.
The known functions of SHPRH and SLC5A9 appeared to be unrelated to the musculoskeletal phenotypes observed in all three families: SHPRH is involved in DNA repair and maintenance of genomic stability while SLC5A9 encodes a sugar transporter primarily expressed in small intestine and kidney. In contrast, mutations in MYH3 frequently cause other forms of distal arthrogryposis, specifically DA2A and DA2B 14 (MIM 601680), and more rarely, DA1 15, 16 . In addition to congenital contractures, persons with DA2A and DA2B variably have short stature, scoliosis, and infrequently pterygia of the neck 17 . Accordingly, we considered Figure S1 ) and her father (Individual III-5, Figure S1 ) using the VCRome 2.1 target capture reagents (Roche Nimblegen) 19 . Sequencing was conducted on Illumina HiSeq2000 as previously described 19 Skeletal abnormalities have not commonly been observed, or at least reported, in persons with DA1, DA2A, or DA2B and mutations in MYH3. Yet, skeletal defects were found in each of the three DA8 families with an MYH3 mutation that we studied. The most common defects observed were vertebral abnormalities including hemivertebrae and vertebral fusions of C1 and C2 or vertebrae of the thoracolumbar spine ( Figure 2) . A similar range of vertebral abnormalities has been reported previously [2] [3] [4] [5] in families with dominantly inherited MPS-as well as both carpal and tarsal fusions. In addition, two persons in Family C had craniosynostosis.
These observations suggest that embryonic myosin plays a role in skeletal development that is perturbed by the mutations in MYH3 that cause DA8. Such a role for embryonic myosin would not be unprecedented as other proteins of the contractile apparatus of skeletal muscle, such as troponin I type 2 (skeletal, fast) (TNNI2, MIM 191043), are expressed in osteoblasts and chondrocytes in long bone growth plates and play a role in skeletal development 25 . Moreover, multiple myosins have been reported to interact with Runx2 in rat osteoblasts and osteoblast differentiation in vitro was associated with the expression of myosin 26 .
To investigate this possibility further, we used primers specific for MYH3 cDNA that we had previously developed 27 to test for MYH3 expression in a variety of human fetal tissues. As expected, MYH3 was expressed in thymus, placenta, heart, and liver ( Figure 4A ). However, whereas MYH3 expression was not detectable in cartilage, it was expressed in bone ( Figure 4A ).
Next, to determine the relative expression levels of MYH3, we conducted a quantitative PCR assay and confirmed MYH3 expression in bone at levels comparable to several other tissues, including brain, with known MYH3 expression 28 ( Figure 4B have been described as "recurrent." Yet, both of these mutations are in EVS and ExAC at frequencies as high as 0.002 (e.g. c.753_754delCT in European-Americans in EVS), suggesting that standing rather than de novo variation contributes to the relatively high incidence of MPS caused by mutations in CHRNG. Moreover, c.459dupA occurs on an identical ~700 kb haplotype in each of the apparently unrelated persons with MPS whom we tested. Therefore, the c.459dupA mutation likely arose many generations ago, and previous attempts did not successfully identify the shared haplotype because of its small size 1 .
Our findings collectively suggest that features such as scoliosis and pterygia observed in individuals with DA8 likely have a different underlying molecular mechanism(s) than in recessive forms of MPS caused by mutations in the genes, CHRNG, CHRND, CHRNA1 9 We failed to identify the cause of dominantly inherited MPS in one family originally diagnosed with DA8 (Family D in Table 1 and Figure S1 ). In retrospect, the phenotype in this family differs from that found in the other DA8 families. Specifically, neither of the affected persons in this family had popliteal or antecubital ptergyia and both persons lacked vertebral fusions. Additionally, each individual had a ventriculoseptal defect. Accordingly, while the lack of an MYH3 mutation in this family could be interpreted as evidence that DA8 is genetically heterogeneous, the alternative is that the phenotype in this family is distinctive enough to prompt delineation of a separate Mendelian condition.
In summary, we used exome sequencing to discover that mutations in MYH3 cause DA8.
The phenotypic overlap among persons with DA8 coupled with physical findings distinct from other DA conditions caused by mutations in MYH3, suggests that the developmental mechanism underlying DA8 differs from other DA conditions or that certain functions of embryonic myosin may be perturbed by disruption of specific residues / domains.
Supplemental Data
Supplemental Data includes 1 figure. receptor channel subtype directs the innervation pattern of skeletal muscle. EMBO Rep. 6, 570-576. 31. Takahashi, M., Kubo, T., Mizoguchi, A., Carlson, C.G., Endo, K., and Ohnishi, K. (2002) . Spontaneous muscle action potentials fail to develop without fetal-type acetylcholine receptors. EMBO Rep. 3, 674-681. Table 1 , where there is a detailed description of the phenotype of each affected individual. Figure S1 provides a pedigree of each family with DA8. A) RNA was isolated from a 17-week old fetus and cDNA was generated using standard protocols 27 . MYH3 primers were predicted to yield amplicons of 313 bp from genomic DNA ("Control") and 206 bp from cDNA. MYH3 cDNA expression was detected in bone thymus, placenta, heart, brain, and liver. Expression was not detected in cartilage, lung, and kidney. B)
Figure Legends
Quantitative PCR was used to assess the relative expression levels of MYH3 cDNA in bone, cartilage, brain, heart, liver and lung. MYH3 cDNA levels were detected in bone at a level similar to that observed in brain and heart and was barely detectable in lung and cartilage.
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